Ultra-low dose oral contraceptives: a game changer in managing puberty menorrhagia-a case series

Muwaffika Taj; Ushadevi Gopalan; Divya Ayyanar

doi:10.18203/2320-1770.ijrcog20242827

Authors

Muwaffika Taj Department of Obstetrics and Gynaecology, Shri Sathya Sai Medical College and Research Institute Under SBV University, Ammapettai, Chengalpattu district, Tamil Nadu, India https://orcid.org/0009-0008-6776-6250
Ushadevi Gopalan Department of Obstetrics and Gynaecology, Shri Sathya Sai Medical College and Research Institute Under SBV University, Ammapettai, Chengalpattu district, Tamil Nadu, India https://orcid.org/0009-0009-2498-1433
Divya Ayyanar Department of Obstetrics and Gynaecology, Shri Sathya Sai Medical College and Research Institute Under SBV University, Ammapettai, Chengalpattu district, Tamil Nadu, India https://orcid.org/0009-0002-3536-4544

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242827

Keywords:

Puberty menorrhagia, COCPs, Puberty, Hormonal contraceptive, Gestodene

Abstract

Puberty menorrhagia, characterized by excessive menstrual bleeding during adolescence, often results from an immature hypothalamic-pituitary-ovarian axis. Effective management is crucial, yet compliance with traditional combined oral contraceptives (COCs) is often low due to side effects like nausea and breakthrough bleeding. This case series investigates the use of ultra-low dose COCs (ULDCOCs) containing 15µg ethinyl oestradiol and 60µg gestodene in five adolescents aged 13-16 years with puberty menorrhagia. The patients presented with prolonged bleeding, irregular cycles, and underlying conditions like polycystic ovarian syndrome (PCOS) and hypothyroidism. Treatment with ULDCOCs resulted in significant improvements: menstrual bleeding reduced, Pictorial Blood Assessment Chart (PBAC) scores dropped from a mean of 103 to 40, and haemoglobin levels improved. Common side effects included mild nausea, breast tenderness, and occasional breakthrough bleeding, which decreased over time. This series suggests that ULDCOCs provide effective cycle regulation and symptom relief with a favourable safety profile in adolescents with puberty menorrhagia. The reduced estrogen content offers fewer side effects while maintaining efficacy. Larger studies are warranted to confirm these findings and establish ULDCOCs as a standard treatment for adolescence-related menstrual disorders.

Metrics

Metrics Loading ...

References

Breehl L, Caban O. Physiology, Puberty. Stat Pearls Publishing. Available at: https://www.ncbi.nlm.nih. Accessed on 17th April 2024.

Koranne PS, Wahane AR. Puberty menorrhagia in modern era: analysis in a tertiary care centre. Int J Reprod Contracept Obstet Gynecol. 2014;3:622-6.

Caufriez A. Menstrual disorders in adolescence: Pathophysiology and treatment. Horm Res 1991;36:156-9.

Munro MG, Critchley HOD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393-408.

Fumero A, Marrero RJ, Peñate W, Bethencourt JM, Barreiro P. Adherence to oral contraception in young women: beliefs, locus of control, and psychological reactance. Int J Environ Res Public Health. 2021;18(21):11308.

Megh M. A Review of gestodene and ultra-low dose ethinyl estradiol in 24 day extended regimen. J Asso Med Women in India. 2015;7:14-20.

Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990;30(4):353-6.

Kulkarni, Nitin, Jagtap, Akshay, Athawale, Prashant. A clinical study of puberty menorrhagia in the modern era at a tertiary health-care centre. Muller J Med Sci Res. 2023;14(2):135.

Roychowdhury J, Chaudhuri S, Sarkar A, Biswas PK. A study to evaluate the aetiological factors and management of puberty menorrhagia. Online J Health Allied Scs. 2008;7(1):5.

Sharma SR. Efficacy and safety of ultralow dose oral contraceptive pills (ULDOCP) in rural Indian women-a prospective, open label study. J Evid Based Med Healthc. 2021;8(11):618-22.

Ahuja M, Pujari P. Ultra-low-dose oral contraceptive pill: a new approach to a conventional requirement. Int J Reprod Contracept Obstet Gynecol. 2017;6:364-70.

Elger W, Steinbeck H, Schillinger E. Endocrine-pharmacological profile of gestodene. Adv Contracept Deliv Syst. 1986;2:182-97.

Gestodene Study Group 322, The safety and contraceptive efficacy of a 24-day low-dose OC regimen containing gestodene 60 μg and ethinyl estradiol 15 μg. Eur J Contracept Reprod Health Care 1999;4:9-15.

Ione CB, Filho CS, Faggion D. Prospective, open- label and non-comparative study to assess cycle control, safety and acceptability of a new contraceptive containing gestodene 60 micro gram and ethinyl estradiol 15 micro grams (Minesse). Contraception. 2006;73(1):30-3.

Ladakan J, Unnop J, Surasak T. Cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microgram and ethinylestrodiol 15 micro gram. J of Med Assoc Thai. 2012;95(5):630-635.

Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril. 1999;72:115-20.

Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103(3):261-7.

Suresh S, Johny ME, Shankari K, Ahamed IU, Yokesh M, Rao MVP. Comparative study of desogestrel- containing oral contraceptive and levonorgestrel- containing oral contraceptive in dysfunctional uterine bleeding. Intern J Res Pharma Sci. 2020;11(4):5678-84.

Jaithitivit L, Jaisamram U, Taneepanichskul S. Cycle control, safety and acceptability of a new oral contraceptive containing ethinyl estradiol15 micrograms and gestodene 60 micrograms. J Med Assoc Thai. 2012;95:630-5.